Repligen to Acquire BioLife in $1.5 Billion Deal
Repligen Corp has agreed to acquire cell therapy tools supplier BioLife Solutions for approximately $1.5 billion, combining cash and stock. The deal aims to expand Repligen's presence in the growing cell therapy market by integrating BioLife’s technology and product portfolio.
Topics: Biotech Cell therapy Pharmaceuticals